• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

cvs? reporting or not?

Quote








Federal regulations will soon stop medical & prescription information collection and dissemination.

CVS has stopped reporting to IMS Health and will not renew any contract.
 




Costco does not report
Walmart does not report
Now CVS stopped reporting

The investors that bought IMS Health and took it private will be holding their hat in their hand.

The investment group that packaged this and sold it to them may have made lots of commission on the deal but there will be hell to pay when IMS is worthless.
 




TPG Investment Group bought IMS in 2009

They were unaware of how inaccurate the data collection actually is.
They were naive to not understand the federal regulation issues that are inevitable.
They are now seeing some big pharmaceutical companies dropping their subscriptions all together.
Glaxo dropped them and JNJ is soon dropping them.

IMS value is on its way to zero
 




Anonymous said:
TPG Investment Group bought IMS in 2009

They were unaware of how inaccurate the data collection actually is.
They were naive to not understand the federal regulation issues that are inevitable.
They are now seeing some big pharmaceutical companies dropping their subscriptions all together.
Glaxo dropped them and JNJ is soon dropping them.

IMS value is on its way to zero
Click to expand...

And it couldn't happen to a nicer company. The pity of it is that Carlucci walked away with millions. Would have loved to see that SOB go down with the ship.
 




Way to go IMS! Your actions should really encourage other data providers to stick with you. No Costco, no WalMart and now no CVS. Rapidly on your way to becoming irrelevant in the US market. I am sure folks will want to pay top dollar for Xponent now. Compensation grade data my @$$. You greedy bast@rds are finally getting what has been coming to you. You held clients like us over a barrel for years. I can tell you one thing, I will be recommending to management that they seek financial remuneration when the data goes in the crapper because you lost CVS. Looks like the perfect time to switch to WoltersKluwer.
 




Anonymous said:
Way to go IMS! Your actions should really encourage other data providers to stick with you. No Costco, no WalMart and now no CVS. Rapidly on your way to becoming irrelevant in the US market. I am sure folks will want to pay top dollar for Xponent now. Compensation grade data my @$$. You greedy bast@rds are finally getting what has been coming to you. You held clients like us over a barrel for years. I can tell you one thing, I will be recommending to management that they seek financial remuneration when the data goes in the crapper because you lost CVS. Looks like the perfect time to switch to WoltersKluwer.
Click to expand...
What a joke...no one is switching to WK. Their President was just forced to resign; they have one major pharma client and everything else doesn't add up to anything. They're so screwed up, the couldn't get SDI to buy them. IMS won't lose anything because no one cares that much about their declining sales forces anymore.
 




All the data providers will be out of business.

Federal regulations soon won't allow for this type of infringement on privacies.

The only data with any type of accuracy is DDD which provides #'s distributed via zip codes.

IMS has always been a "scam" and the trend by pharma is dropping them anyways.
 




Top Bottom
Back
Quote